Skip to main content
OMER logo

Omeros Corporation (OMER) Stock: Price, Forecast & Analyst Target

Omeros Corporation (OMER) — MoonshotScore 23/100 (Weak band), calculated Nov 18, 2026. Price $14.01 (-3.71%), as of the Nov 19, 2026 trading session; market cap $1.04B.

Educational signal · not a buy or sell recommendation · How to read this

$14.01 −$0.54 (-3.71%) Market Cap $1.04B

Omeros Corporation · OMER · NASDAQ

Omeros Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutics for inflammation, complement-mediated diseases, and cancers. Their pipeline includes clinical programs targeting various disorders, including addiction and compulsive disorders.

Price as of Nov 19, 2026

Key Statistics

23 of 100

MoonshotScore v2 · Omeros (OMER)

Weak
Business Quality Solid (61)
Financial Safety Strained (27)
Valuation Full (56)
Growth Durability Compounding (88)
Momentum Rising (79)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite growth, but a strained balance sheet and a full valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and reported profit not backed by cash flow. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Compounding; Momentum: Rising.

  • quarterly revenue $29M (Q2 FY2026, quarter ended Jun 30, 2026)
  • EPS beat 2 of the last 4 reports
  • Altman Z -1.36 · Piotroski F 5

Holding back: balance-sheet strain

Helping: durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for OMER (57 recorded, newest six shown)
RecordedScoreBand
33Weak
32Weak
32Weak
32Weak
23Weak
23Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$14.01
Change on the day-3.71%
Market capitalisation$1.04B—
Price / earnings (trailing)8.75
Shares traded on the day1.29M

Price & events

Other perspectives

Council score for Omeros (OMER): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Weak
Valuation Neutral
Growth Durability Strong
Momentum Moderate

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Moderate
Margin of Safety Undervalued
Profit Margin Strong
Gross Margin Strong

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Four of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Englander-style lens, Munger lens (margin of safety) and Financial health lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Omeros (OMER), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Omeros Corporation (OMER) is listed on NASDAQ. It employs 175 people. In Q2 FY2026 it reported revenue of $29M and net income of $13M. The market values it at $1.04B.

2 · Latest results

What do the latest results show for Omeros (OMER)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $29M. Against analyst estimates the company has EPS beat 2 of the last 4 reports.

Quarterly income statement — 2 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$29M$13M$0.15 (diluted)
Q1 FY2026$10M$56M$0.62 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Omeros (OMER)?

Short answer

The MoonshotScore pillars rate durable growth, positive momentum as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z -1.36 · Piotroski F 5. Trailing ratios: ROA -12.1% · current ratio 2.27.

4 · What to check next?

What should you watch next at Omeros (OMER)?

Short answer · as of

Current published price targets run low $22.00 · high $33.00 · consensus $27.50 · median $27.50 against a quoted price of $14.01 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Omeros compare with its peers?

Short answer

Omeros's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eton Pharmaceuticals, Inc. (ETON) Same industry, near in market value$61.99 Nov 18, 2026$1.79B98 5-pillar Nov 18, 2026
Nurix Therapeutics, Inc. (NRIX) Same industry, near in market value$14.10 Nov 18, 2026$1.54B97 5-pillar Nov 18, 2026
Innoviva, Inc. (INVA) Same industry, near in market value$18.40 Nov 18, 2026$1.31B96 5-pillar Nov 18, 2026
Harmony Biosciences Holdings, Inc. (HRMY) Same industry, near in market value$33.11 Nov 18, 2026$1.94B96 5-pillar Nov 18, 2026
Vertex Pharmaceuticals Incorporated (VRTX) Named competitor$536.45 Nov 18, 2026$136B90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
AnaptysBio, Inc. (ANAB) Same industry, near in market value$47.40 Nov 19, 2026$1.41B76 5-pillar Nov 18, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Named competitor$147.82 Nov 19, 2026$19.8B72 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.17 Nov 19, 2026$861M69 5-pillar Nov 18, 2026
LB Pharmaceuticals Inc (LBRX) Same industry, near in market value$40.04 Nov 19, 2026$1.30B69 5-pillar Nov 18, 2026
Vor Biopharma, Inc. (VOR) Same industry, near in market value$18.52 Nov 19, 2026$1.14B66 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.78 Nov 19, 2026$1.03B64 5-pillar Nov 18, 2026
Omeros (OMER) — this page$14.01$1.04B23

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$22.00 – $33.00
Consensus target
$27.50
Median target
$27.50

Consensus record · Captured .

Measured against a quoted price of $14.01 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held OMER in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported OMER in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Omeros (OMER)?

Read these with our analysis →

What Investors Ask About Omeros (OMER)

These answers are editorial: 1 of these 9 answers is drawn from the OMER research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for OMER?

OMER carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Omeros Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutics for inflammation, complement-mediated diseases, and cancers.

Is OMER a good stock to buy?

Stock Expert AI does not rate OMER buy, sell or hold. Omeros Corporation carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the OMER stock price today?

The last price recorded for Omeros Corporation (OMER), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the OMER price target?

The analyst consensus price target for Omeros Corporation (OMER), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What do analysts say about OMER stock?

Analysts' views on Omeros Corporation (OMER) are varied, reflecting the inherent risks and potential rewards of a biotechnology company with a diverse pipeline. Key valuation metrics often focus on the potential of Narsoplimab and other clinical programs.

What are the key factors to evaluate for OMER?

Omeros Corporation (OMER) holds a MoonshotScore in the low range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Focus on orphan indications provides potential for accelerated regulatory pathways and market exclusivity. Not financial advice.

How frequently does OMER data refresh on this page?

OMER's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven OMER's recent stock price performance?

Omeros Corporation (OMER) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse pipeline of clinical and preclinical programs. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider OMER overvalued or undervalued right now?

The trailing P/E of Omeros Corporation (OMER) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 14 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.